Compare Nirsevimab to Palivizumab for RSV Prevention
October 2023
You’ll hear buzz about nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in young children.
RSV is the most common cause of hospitalization in US infants...and typically circulates from October through March. Almost 8 in 10 kids under age 2 who get hospitalized for RSV are otherwise healthy.
Nirsevimab is a monoclonal antibody given IM in the hospital or clinic...similar to palivizumab (Synagis). But nirsevimab has a broader indication...palivizumab is only for certain high-risk kids.
Practical advice for a better career, with unlimited access to CE
Hospital Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote